MX362995B - Derivado de aminotriazina y composicion farmaceutica que comprende el mismo. - Google Patents

Derivado de aminotriazina y composicion farmaceutica que comprende el mismo.

Info

Publication number
MX362995B
MX362995B MX2015016877A MX2015016877A MX362995B MX 362995 B MX362995 B MX 362995B MX 2015016877 A MX2015016877 A MX 2015016877A MX 2015016877 A MX2015016877 A MX 2015016877A MX 362995 B MX362995 B MX 362995B
Authority
MX
Mexico
Prior art keywords
derivatives
amino
pharmaceutical composition
composition containing
triazine
Prior art date
Application number
MX2015016877A
Other languages
English (en)
Other versions
MX2015016877A (es
Inventor
Kai Hiroyuki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2015016877A publication Critical patent/MX2015016877A/es
Publication of MX362995B publication Critical patent/MX362995B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un compuesto nuevo que tiene una actividad antagonística del receptor p2x3 y/o p2x2/3. Un compuesto de fórmula (I): Fórmula Química 1 (ver Fórmula) en donde Ra y Rb, y Rd y Re son tomados juntos para formar oxo o similares; R4a y R4b son hidrógeno o similares; n es 1 o similares; R2 es arilo o similares; s y s' es 0 o similares; R9 y R9' son halógeno o similares; R20a y R20b son hidrógeno, alquilo o similares; u es 1 hasta 4; R13 es hidrógeno o similares, o su sal farmacéuticamente aceptable.
MX2015016877A 2013-06-14 2014-06-13 Derivado de aminotriazina y composicion farmaceutica que comprende el mismo. MX362995B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013125134 2013-06-14
PCT/JP2014/065678 WO2014200078A1 (ja) 2013-06-14 2014-06-13 アミノトリアジン誘導体およびそれらを含有する医薬組成物

Publications (2)

Publication Number Publication Date
MX2015016877A MX2015016877A (es) 2016-04-07
MX362995B true MX362995B (es) 2019-03-01

Family

ID=52022364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016877A MX362995B (es) 2013-06-14 2014-06-13 Derivado de aminotriazina y composicion farmaceutica que comprende el mismo.

Country Status (20)

Country Link
US (2) US9732060B2 (es)
EP (1) EP3009432B1 (es)
JP (1) JP6132371B2 (es)
KR (2) KR20170116177A (es)
CN (1) CN105452234B (es)
AR (1) AR096620A1 (es)
AU (1) AU2014279116B2 (es)
BR (1) BR112015031079B1 (es)
CA (1) CA2915325C (es)
DK (1) DK3009432T3 (es)
EA (1) EA030198B1 (es)
ES (1) ES2675528T3 (es)
IL (1) IL243042A0 (es)
MX (1) MX362995B (es)
PH (1) PH12015502775A1 (es)
PL (1) PL3009432T3 (es)
SG (1) SG11201510179PA (es)
TR (1) TR201809085T4 (es)
TW (1) TWI637949B (es)
WO (1) WO2014200078A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
JP6075621B2 (ja) * 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
CN103153968B (zh) 2010-08-10 2016-02-03 盐野义制药株式会社 三唑衍生物及含有其的具有镇痛作用的药物组合物
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
WO2015099107A1 (ja) 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
JPWO2016084922A1 (ja) * 2014-11-28 2017-09-07 塩野義製薬株式会社 １，２，４−トリアジン誘導体およびその医薬組成物
US10774051B2 (en) 2015-04-24 2020-09-15 Shionogi & Co., Ltd. 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same
WO2017160569A1 (en) * 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
AU2017237929B2 (en) 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
WO2018074390A1 (ja) 2016-10-17 2018-04-26 塩野義製薬株式会社 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
KR102742881B1 (ko) 2018-06-29 2024-12-16 삼성디스플레이 주식회사 디스플레이 장치
KR102548987B1 (ko) 2018-08-09 2023-06-29 삼성디스플레이 주식회사 디스플레이 장치
ES2963702T3 (es) 2018-10-05 2024-04-01 Shionogi & Co Medicina para tratar la tos crónica
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
TWI889708B (zh) * 2019-09-19 2025-07-11 日商塩野義製藥股份有限公司 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
TW202203930A (zh) * 2020-04-03 2022-02-01 日商塩野義製藥股份有限公司 睡眠時呼吸中止症候群治療用醫藥
TW202203929A (zh) * 2020-04-03 2022-02-01 日商塩野義製藥股份有限公司 疼痛治療用醫藥
EP4151219A4 (en) * 2020-05-15 2024-05-15 Shionogi & Co., Ltd DRUG COMPOSITION WITH INHIBITED IMPURITIES PRODUCTION
LT4122926T (lt) 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
US20240287026A1 (en) * 2021-06-04 2024-08-29 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Triazinylmethylcycloalkylcarboxylic acid derivative, and pharmaceutical composition and use thereof
CN113801097B (zh) * 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113773300B (zh) * 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
CN113620888B (zh) * 2021-09-27 2023-06-06 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和应用
WO2023054292A1 (ja) 2021-09-28 2023-04-06 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
AU2022353486A1 (en) 2021-09-28 2024-05-02 National University Corporation Hokkaido University Pharmaceutical composition containing triazine derivative
EP4289432A4 (en) 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES
US20250025459A1 (en) * 2021-11-26 2025-01-23 Shionogi & Co., Ltd. Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
WO2023054732A2 (ja) 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
CN115650959B (zh) * 2022-05-20 2023-10-20 南京济群医药科技股份有限公司 化合物的制备方法或纯化方法
WO2024169781A1 (zh) * 2023-02-15 2024-08-22 南京明德新药研发有限公司 嘧啶酮衍生物及其在药学上的应用
WO2025255215A1 (en) 2024-06-05 2025-12-11 Shionogi-Apnimed Sleep Science, Llc Methods and compositions for treating sleep apnea

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598815A (en) 1968-10-25 1971-08-10 Goodrich Co B F Bis-(hydroxyphenylalkylene) alkyl isocyanurates
JPS5132324A (en) 1974-09-12 1976-03-18 Fuji Photo Film Co Ltd Netsugenzokankozairyo
CH622536A5 (es) 1976-07-08 1981-04-15 Ciba Geigy Ag
US4158724A (en) 1976-10-18 1979-06-19 Ciba-Geigy Corporation Tris-tetrazoles as chemical blowing agents
CH623840A5 (es) 1976-10-18 1981-06-30 Ciba Geigy Ag
GB1599518A (en) 1977-02-21 1981-10-07 Ici Ltd 1,3,5-triazine-2,6-diones and pharmaceutical compositions thereof
ATE698T1 (de) 1978-05-26 1982-03-15 Imperial Chemical Industries Plc Analgetische 6-acylaminot etrahydro-1,3,5-triazin-2,4-dion-derivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.
JPS57144269A (en) 1981-03-03 1982-09-06 Taiho Yakuhin Kogyo Kk Triazine derivative and its preparation
EP0110828B1 (de) 1982-11-26 1988-01-20 Ciba-Geigy Ag Farbphotographisches Aufzeichnungsmaterial
JPS62156110A (ja) 1985-12-27 1987-07-11 Res Inst For Prod Dev 測鎖にイソシアヌレ−ト構造を含む吸着能力を有する重合体
JPS62156110U (es) 1986-03-26 1987-10-03
ATE111911T1 (de) 1989-06-05 1994-10-15 Daiichi Seiyaku Co Heterocyclische triazin- oder triazolo- verbindungen mit serotonin 2-rezeptor- antagonisten-wirkung.
RU2057754C1 (ru) 1989-06-05 1996-04-10 Дайити Фармасьютикал Ко., Лтд. Гетероциклические соединения или их кислотно-аддитивные соли
DE4141721A1 (de) 1991-12-18 1993-06-24 Bayer Ag Substituierte heterocyclyltriazindione
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
WO1999052881A1 (en) 1998-04-15 1999-10-21 Sagami Chemical Research Center 2-anilinopyrimidinone derivatives, intermediates in the production thereof, process for producing the same and pesticides containing the same as the active ingredient
JP2995293B1 (ja) 1998-08-25 1999-12-27 工業技術院長 １，６‐ジ置換‐１，３，５‐トリアジン‐２，４（１ｈ，３ｈ）‐ジオン化合物の製造方法
US6177437B1 (en) 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6713486B1 (en) 1999-03-04 2004-03-30 Korea Research Institute Of Chemical Technology Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
JP4674676B2 (ja) 1999-11-08 2011-04-20 公益財団法人相模中央化学研究所 ２−置換アミノピリミジノン誘導体、それらの製造方法並びにそれらを有効成分とする殺虫、殺ダニ剤
AU2001227084A1 (en) 2000-01-25 2001-08-07 Japan Tobacco Inc. N-arylhydrazide compounds and use thereof as drugs
US20020049320A1 (en) 2000-04-27 2002-04-25 American Cyanamid Company 6-amino-2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives and methods for the solid phase synthesis thereof
DK1392643T3 (da) 2001-05-18 2006-01-30 Abbott Lab (1S)-1,2,3,4-tetrahydro-1-naphthalenylbenzamider, der er trisubstituerede ved N, og som inhiberer receptorer indeholdende P2X3 og P2X2/3
JPWO2004054617A1 (ja) 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
WO2005009980A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
CA2557372C (en) 2004-03-05 2013-01-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
JP2008507368A (ja) 2004-07-22 2008-03-13 デュスカ サイエンティフィック カンパニー 肺疾患を診断、モニタリングおよび治療するための方法
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
KR20080006564A (ko) 2005-03-24 2008-01-16 얀센 파마슈티카 엔.브이. 프로키네티신 1 수용체 길항제
JP2008537548A (ja) 2005-03-24 2008-09-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ プロキネチシン１受容体
EP1869006A1 (en) 2005-03-24 2007-12-26 Janssen Pharmaceutica N.V. Pyrimidindione derivatives as prokineticin 2 receptor antagonists
US8507415B2 (en) 2005-05-03 2013-08-13 Southwest Research Institute Lubricant oils and greases containing nanoparticle additives
MX2007013595A (es) 2005-05-04 2008-01-24 Renovis Inc Compuestos heterociclicos fusionados y composiciones y usos de estos.
MX2008002014A (es) 2005-08-15 2008-03-27 Hoffmann La Roche Derivados de piperidina y piperazina como antagonistas de p2x3.
CN101300012B (zh) 2005-09-01 2011-09-14 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用
MX2008002731A (es) 2005-09-01 2008-03-26 Hoffmann La Roche Diaminopirimidinas como moduladores de p2x3 y p3x2/3.
EP1924564B1 (en) 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
WO2007079163A2 (en) 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 1 receptor antagonists
CA2635845A1 (en) 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 2 receptor antagonists
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
KR20110089463A (ko) 2006-07-24 2011-08-08 한국화학연구원 신규 ｈｉｖ 역전사 효소 억제제
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
WO2008127591A2 (en) 2007-04-13 2008-10-23 Schering Corporation Pyrimidinedione derivatives and use thereof
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP2009007258A (ja) 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd Ｐａｉ−１産生抑制作用を有する３−アニリノ−２−シクロアルケノン誘導体
JP2011502154A (ja) 2007-10-30 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノヘテロアリールを含むプロキネチシン１受容体拮抗物質連邦政府支援研究又は開発に関する陳述下に記述される本発明の研究及び開発は、連邦政府の支援によるものではない。
KR20100124262A (ko) 2008-02-13 2010-11-26 에자이 알앤드디 매니지먼트 가부시키가이샤 비시클로아민 유도체
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
MX2011004570A (es) 2008-10-31 2011-06-17 Merck Sharp & Dohme Antagonistas del receptor p2x3 para el tratamiento del dolor.
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
SG177308A1 (en) 2009-06-22 2012-02-28 Hoffmann La Roche Novel biphenyl and phenyl-pyridine amides
MX2012001646A (es) 2009-08-05 2012-03-21 Du Pont Pesticidas mesoionicos.
CA2806572C (en) 2010-07-30 2018-10-30 Expression Pathology, Inc. C-src selected reaction monitoring assay
JP6075621B2 (ja) 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
CN103153968B (zh) * 2010-08-10 2016-02-03 盐野义制药株式会社 三唑衍生物及含有其的具有镇痛作用的药物组合物
ES2759615T3 (es) 2011-04-01 2020-05-11 Univ Utah Res Found Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
TW201331188A (zh) * 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
WO2013118855A1 (ja) 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物

Also Published As

Publication number Publication date
JPWO2014200078A1 (ja) 2017-02-23
PH12015502775A1 (en) 2016-03-21
KR101813411B1 (ko) 2017-12-28
KR20170116177A (ko) 2017-10-18
US20160115151A1 (en) 2016-04-28
CA2915325C (en) 2021-09-14
AU2014279116A1 (en) 2015-12-24
TW201529567A (zh) 2015-08-01
IL243042A0 (en) 2016-02-01
US20170362199A1 (en) 2017-12-21
US10065941B2 (en) 2018-09-04
US9732060B2 (en) 2017-08-15
AU2014279116B2 (en) 2016-11-10
ES2675528T3 (es) 2018-07-11
CA2915325A1 (en) 2014-12-18
AR096620A1 (es) 2016-01-20
CN105452234A (zh) 2016-03-30
TWI637949B (zh) 2018-10-11
DK3009432T3 (en) 2018-07-16
BR112015031079A2 (pt) 2017-07-25
MX2015016877A (es) 2016-04-07
EP3009432A1 (en) 2016-04-20
EA201690019A1 (ru) 2016-05-31
CN105452234B (zh) 2018-03-06
WO2014200078A1 (ja) 2014-12-18
SG11201510179PA (en) 2016-01-28
EA030198B1 (ru) 2018-07-31
JP6132371B2 (ja) 2017-05-24
KR20160018807A (ko) 2016-02-17
TR201809085T4 (tr) 2018-07-23
EP3009432B1 (en) 2018-04-25
PL3009432T3 (pl) 2018-09-28
EP3009432A4 (en) 2016-11-02
BR112015031079B1 (pt) 2022-08-02

Similar Documents

Publication Publication Date Title
MX2015016877A (es) Derivado de aminotriazina y composicion farmaceutica que comprende el mismo.
PH12014502540A1 (en) Benzimidazole-proline derivatives
MY201832A (en) Sulfonamide compounds and use thereof
PH12015500780A1 (en) Rsv antiviral compounds
PH12016500806A1 (en) Urea derivative or pharmacologically acceptable salt thereof
SG10201805024YA (en) Methods useful in the synthesis of halichondrin b analogs
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
GB201101517D0 (en) Receptor antagonists
MX2016012451A (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina.
BR112015021586A2 (pt) formulações de morfina
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX340033B (es) Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
MX2018001517A (es) Derivados sustituidos de guanidina.
PH12017500119A1 (en) Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
PH12016500461A1 (en) Polyethylene glycol-containing composition
PH12015501146A1 (en) Hydantoin derivative
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
PH12018502246A1 (en) Substituted fused pyrimidinone compounds
EA201690908A1 (ru) Пиразолопиримидиновые соединения
WO2013184570A3 (en) Synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
IN2013MU03565A (es)
MX2019007786A (es) Compuestos sustituidos de guanidina.
EA201400882A1 (ru) Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях
BR112014000439A2 (pt) ferramenta de corte de fundo de poço e método
IN2013MU02612A (es)